Search
for
Sort by
Research 31–60 of 462
- Urticaria, Drug Hypersensitivity Rashes, Nodules and Tumors, and Atrophic Diseases
- Drug-Induced Skin, Nail and Hair Disorders
- Lithium therapy associated with hidradenitis suppurativa: Case report and a review of the dermatologic side effects of lithium
- Drug-induced acne
- Neutralization of IL-8 Prevents the Induction of Dermatologic Adverse Events Associated with the Inhibition of Epidermal Growth Factor Receptor
- Sorafenib-Associated Facial Acneiform Eruption
- Dermatologic adverse events associated with chemotherapy and targeted anticancer therapy
- A Case of Cicatricial Alopecia Associated with Erlotinib
- Review article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel disease
- Cutaneous reactions to targeted therapies in children with CNS tumors: A cross‐sectional study
- Dermatolojik Problemler ve COVID-19
- Cutaneous Lupus Erythematosus
- Oral zinc sulphate in treatment of patients with thallium poisoning: A clinical therapeutic trial
- Cutaneous manifestations of HIV infection other than Kaposi's sarcoma: Clinical and histologic aspects
- Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects
- Spontaneous cutaneous adverse drug reaction reports—An analysis of a 10‐year dataset in Singapore
- Concomitant occurrence of acneiform eruption, alopecia areata, and urticaria during adalimumab treatment in a patient with pustulosis palmoplantaris: Case report and literature review
- The pharmacovigilance analysis of adverse events of erlotinib based on the open access FAERS database
- Dermatologic adverse events associated with afatinib: an oral ErbB family blocker
- Cutaneous side-effects of EGFR inhibitors and their management.
- Cutaneous Toxicities of Advanced Treatment for Cutaneous Melanoma: A Prospective Study from a Single-Center Institution
- Cutaneous adverse events to systemic antineoplastic therapies: a retrospective study in a public oncologic hospital
- Treatment of Cultured Sebocytes with an EGFR Inhibitor Does Not Lead to Significant Upregulation of Inflammatory Biomarkers
- Pharmacotherapy of plexiform neurofibromas in patients with neurofibromatosis type 1. Possible adverse events and their management
- Cutaneous Side Effects of Modern Targeted Therapy and Immunotherapy in Patients with Dermatological Malignancies
- First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors
- Skin Manifestations of Rheumatological Diseases
- Safety of Tyrosine Kinase Inhibitors in Patients With Differentiated Thyroid Cancer: Real-World Use of Lenvatinib and Sorafenib in Korea
- Dermatologic adverse events in pediatric patients receiving targeted anticancer therapies: A pooled analysis
- IL-36γ drives skin toxicity induced by EGFR/MEK inhibition and commensal Cutibacterium acnes